Needham reiterates Hold rating on Teladoc stock after Q2 results

Published 30/07/2025, 11:48
Needham reiterates Hold rating on Teladoc stock after Q2 results

Investing.com - Needham maintained its Hold rating on Teladoc (NYSE:TDOC), currently trading at $7.53, following the telehealth company’s second-quarter 2025 earnings report. According to InvestingPro data, the company maintains a healthy gross profit margin of 70.5% despite recent challenges.

Teladoc delivered better-than-expected results for both revenue and earnings in the second quarter, but the company did not raise its full-year 2025 guidance despite the quarterly beat. The stock has fallen 12.2% in the past week, with InvestingPro analysis showing 2 analysts revising their earnings expectations downward for the upcoming period.

The research firm identified BetterHelp, Teladoc’s mental health service, as the main factor behind the company’s cautious outlook, noting it faces increasing competition from providers that accept insurance coverage versus BetterHelp’s cash payment model.

Teladoc is attempting to address these challenges through its acquisition of Uplift and by expanding insurance options for BetterHelp therapists, though Needham expressed concerns about execution risks in this transition.

The firm remains neutral on Teladoc until it sees clearer evidence of fundamental improvement, particularly given the potential margin pressure from insurance reimbursements that could limit profitability growth.

In other recent news, Teladoc Inc reported its earnings for the second quarter of 2025, surpassing expectations. The company achieved an earnings per share of -$0.19, beating the forecasted -$0.26. Revenue for the quarter reached $631.9 million, slightly above the anticipated $622.54 million. These results reflect a stronger-than-expected performance for Teladoc. Despite the positive earnings surprise, broader market concerns were noted. The company’s financial results indicate solid revenue growth, which may interest investors. Such developments are crucial as they provide insight into Teladoc’s current financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.